264 related articles for article (PubMed ID: 11259096)
1. Chromogranin A and the alpha-subunit of glycoprotein hormones in medullary thyroid carcinoma and phaeochromocytoma.
Guignat L; Bidart JM; Nocera M; Comoy E; Schlumberger M; Baudin E
Br J Cancer; 2001 Mar; 84(6):808-12. PubMed ID: 11259096
[TBL] [Abstract][Full Text] [Related]
2. A new human chromogranin 'A' immunoradiometric assay for the diagnosis of neuroendocrine tumours.
Bernini GP; Moretti A; Ferdeghini M; Ricci S; Letizia C; D'Erasmo E; Argenio GF; Salvetti A
Br J Cancer; 2001 Mar; 84(5):636-42. PubMed ID: 11237384
[TBL] [Abstract][Full Text] [Related]
3. [Sipple syndrome (bilateral phaeochromocytoma medullary C-cell carcinoma of the thyroid gland) with exceptionally prolonged clinical course].
Kovarik J; Silberbauer K; Woloszczuk W; Krisch K; Geyer G
Wien Klin Wochenschr; 1982 Jun; 94(13):340-5. PubMed ID: 6127842
[TBL] [Abstract][Full Text] [Related]
4. The role of chromogranin A in the management of patients with phaeochromocytoma.
Grossrubatscher E; Dalino P; Vignati F; Gambacorta M; Pugliese R; Boniardi M; Rossetti O; Marocchi A; Bertuzzi M; Loli P
Clin Endocrinol (Oxf); 2006 Sep; 65(3):287-93. PubMed ID: 16918946
[TBL] [Abstract][Full Text] [Related]
5. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones.
Nobels FR; Kwekkeboom DJ; Coopmans W; Schoenmakers CH; Lindemans J; De Herder WW; Krenning EP; Bouillon R; Lamberts SW
J Clin Endocrinol Metab; 1997 Aug; 82(8):2622-8. PubMed ID: 9253344
[TBL] [Abstract][Full Text] [Related]
6. Chromogranin A storage and secretion: sensitivity and specificity for the diagnosis of pheochromocytoma.
Hsiao RJ; Parmer RJ; Takiyyuddin MA; O'Connor DT
Medicine (Baltimore); 1991 Jan; 70(1):33-45. PubMed ID: 1988765
[TBL] [Abstract][Full Text] [Related]
7. Chromogranin A: an additional tumor marker for postoperative recurrence and metastases of medullary thyroid carcinomas?
Franke WG; Pinkert J; Runge R; Bredow J; Wunderlich G; Koch R
Anticancer Res; 2000; 20(6D):5257-60. PubMed ID: 11326706
[TBL] [Abstract][Full Text] [Related]
8. Argyrophilia and chromogranin A and B immunostaining in patients with sporadic medullary thyroid carcinoma. A critical appraisal of their prognostic utility.
Scopsi L; Sampietro G; Boracchi P; Collini P
J Pathol; 1998 Apr; 184(4):414-9. PubMed ID: 9664908
[TBL] [Abstract][Full Text] [Related]
9. Secretion of chromogranin A by peptide-producing endocrine neoplasms.
O'Connor DT; Deftos LJ
N Engl J Med; 1986 May; 314(18):1145-51. PubMed ID: 3007986
[TBL] [Abstract][Full Text] [Related]
10. [Pheochromocytoma--pathohistologic and immunohistochemical aspects].
Tatić S; Havelka M; Paunović I; Bozić V; Diklic A; Brasanac D; Janković R; Jancić-Zguricas M
Srp Arh Celok Lek; 2002 Jul; 130 Suppl 2():7-13. PubMed ID: 12584991
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical study of chromogranin in 100 cases of pheochromocytoma, carotid body tumour, medullary thyroid carcinoma and carcinoid tumour.
Kimura N; Sasano N; Yamada R; Satoh J
Virchows Arch A Pathol Anat Histopathol; 1988; 413(1):33-8. PubMed ID: 3131955
[TBL] [Abstract][Full Text] [Related]
12. Tumour markers in neuroendocrine tumours.
Oberg K; Janson ET; Eriksson B
Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S160-2. PubMed ID: 10604122
[TBL] [Abstract][Full Text] [Related]
13. Multiple endocrine neoplasia 2A due to a unique C609S RET mutation presents with pheochromocytoma and reduced penetrance of medullary thyroid carcinoma.
Kinlaw WB; Scott SM; Maue RA; Memoli VA; Harris RD; Daniels GH; Porter DM; Belloni DR; Spooner ET; Ernesti MM; Noll WW
Clin Endocrinol (Oxf); 2005 Dec; 63(6):676-82. PubMed ID: 16343103
[TBL] [Abstract][Full Text] [Related]
14. [Analysis of laboratory data of 155 patients with pheochromocytoma-paraganglioma syndrome diagnosed during the past 20 years].
Balog B; Tőke J; Róna K; Szücs N; Igaz P; Pusztai P; Sármán B; Gláz E; Kiss R; Patócs A; Rácz K; Tóth M
Orv Hetil; 2015 Apr; 156(16):626-35. PubMed ID: 25864138
[TBL] [Abstract][Full Text] [Related]
15. Effects of slow-release octreotide on urinary metanephrine excretion and plasma chromogranin A and catecholamine levels in patients with malignant or recurrent phaeochromocytoma.
Lamarre-Cliche M; Gimenez-Roqueplo AP; Billaud E; Baudin E; Luton JP; Plouin PF
Clin Endocrinol (Oxf); 2002 Nov; 57(5):629-34. PubMed ID: 12390337
[TBL] [Abstract][Full Text] [Related]
16. Chromogranin A as a marker of neuroendocrine histogenesis of tumours: an immunoelectron microscopic study with considerations about the influence of fixation and embedding media on immunolabelling.
Leone BE; Taccagni GL; Dell'Antonio G; Cantaboni A
Basic Appl Histochem; 1990; 34(2):143-53. PubMed ID: 2222401
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic difficulties associated with phaeochromocytoma--4 case illustrations.
Tan KE; Fok AC; Eng PH; Khoo DH
Singapore Med J; 1997 Nov; 38(11):493-6. PubMed ID: 9550913
[TBL] [Abstract][Full Text] [Related]
18. The biochemical diagnosis, localization and follow up of phaeochromocytoma: the role of plasma and urinary catecholamine measurements.
Jones DH; Reid JL; Hamilton CA; Allison DJ; Welbourn RB; Dollery CT
Q J Med; 1980; 49(195):341-61. PubMed ID: 7465766
[TBL] [Abstract][Full Text] [Related]
19. Serum calcitonin in thyroid disorders and in pheochromocytoma kindred.
Hornicek FJ; Danowski TS; Robinson SM; Sweeney KT; Malinin GI
Ann Clin Lab Sci; 1986; 16(2):103-7. PubMed ID: 3963731
[TBL] [Abstract][Full Text] [Related]
20. Urinary catecholamines and the diagnosis of phaeochromocytoma in Auckland.
McNeil AR; Woollard GA
N Z Med J; 1997 Sep; 110(1051):331-3. PubMed ID: 9323371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
